VYGR Earnings

VYGR reported its earnings on 2025-08-05, showcasing a revenue of against an estimate of , resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.48 by 0%. The stock experienced a 5.3% price change on the earnings day and a -2.18% change over the next five days, reflecting market reactions to the results.

Following VYGR's earnings announcement on 2025-08-05, the stock price moved by 5.3% on the day of the release. Over the subsequent five days, it saw a -2.18% change. Historically, VYGR's stock price tends to shift by an average of -5.38% in the 10 days leading up to earnings and 1.03% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate VYGR's annual revenue to reach 10.49M, while the EPS is projected at -0.53. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between VYGR's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, VYGR's stock price typically moves by -5.38% in the 10 days before its earnings and 1.03% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.53 and revenue of 10.49M.

The earnings call revealed missed EPS expectations, indicating financial instability. Despite promising partnerships and clinical milestones, setbacks in gene therapy and reliance on partnerships pose risks. Regulatory challenges and market competition further add to uncertainties. The Q&A highlighted management's evasive responses and potential risks in clinical trials. Overall, the negative sentiment from financial results and uncertainties outweighs the positives, suggesting a negative stock price reaction.